<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297322</url>
  </required_header>
  <id_info>
    <org_study_id>PTL 0243</org_study_id>
    <nct_id>NCT01297322</nct_id>
  </id_info>
  <brief_title>RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT)</brief_title>
  <acronym>RESPECT</acronym>
  <official_title>A Multi-Center, Prospective, Randomized, Controlled, Trial to Evaluate the Safety and Efficacy of the Cardiva VASCADE VCS vs. Manual Compression for the Management of the Femoral Arteriotomy After Percutaneous Endovascular Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiva Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiva Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to demonstrate the safety and effectiveness of the Cardiva
      VASCADE™ Vascular Closure System (VCS) in sealing femoral arterial access sites. Hypothesis:
      The Cardiva VASCADE™ VCS provides times to hemostasis (TTH) and time to ambulation (TTA)
      results that are less than manual compression by a clinically meaningful and statistically
      significant margin. The rate of major access site-related complications with the Cardiva
      VASCADE™ VCS is non-inferior to the major complication rates of manual compression for
      sealing femoral arterial access sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, controlled multi-center clinical trial designed to evaluate the
      safety and effectiveness of the study device in sealing femoral arterial access sites and
      providing reduced times to hemostasis and ambulation compared with manual compression at the
      completion of diagnostic or interventional endovascular procedures performed through 6 Fr or
      7 Fr introducer sheaths. Subjects will be randomized in a 2:1 treatment device to control
      ratio.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Hemostasis (TTH)</measure>
    <time_frame>Up to 1 hour</time_frame>
    <description>Primary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and first observed and confirmed arterial hemostasis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Combined Access Site-related Major Complications</measure>
    <time_frame>30 days +/- 7 days</time_frame>
    <description>Primary safety endpoint
Access site-related bleeding requiring transfusion;
Vascular injury requiring repair (via surgery, ultrasound guided compression, transcatheter embolization or stent graft);
New ipsilateral lower extremity ischemia causing a threat to the viability of the limb and requiring surgical or additional percutaneous intervention. This compromised blood flow is documented by subject symptoms, physical exam and/or a decreased or absent blood flow on lower extremity angiogram.;
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization;
New onset access site-related neuropathy in the ipsilateral lower extremity requiring surgical repair;
Permanent access site-related nerve injury. (&gt; 30 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Ambulation (TTA)</measure>
    <time_frame>Up to 1 day</time_frame>
    <description>Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject stands and walks 20 feet without evidence of arterial re-bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge Eligibility (TTDE)</measure>
    <time_frame>Up to 2 days</time_frame>
    <description>Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject is medically able to be discharged based solely on the assessment of the access site, as determined by the medical team</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge (TTHD)</measure>
    <time_frame>Up to 2 days</time_frame>
    <description>Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject is actually discharged from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Up to 1 day</time_frame>
    <description>Secondary effectiveness endpoint - ability to deploy the delivery system, deliver the collagen, and achieve hemostasis with VASCADE alone or with adjunctive compression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>30 days +/- 7 days</time_frame>
    <description>Secondary effectiveness endpoint - attainment of final hemostasis using any method and freedom from major vascular complications through 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Combined Minor Access Site Complications</measure>
    <time_frame>30 days +/- 7 days</time_frame>
    <description>Secondary safety endpoint
Access site-related bleeding requiring greater than 30 minutes to achieve hemostasis;
Access site-related hematoma &gt; 6 cm;
Late access site-related bleeding (following hospital discharge);
Ipsilateral lower extremity arterial emboli;
Ipsilateral deep vein thrombosis;
Access site-related vessel laceration;
Access site wound dehiscence;
Localized access site infection treated with intramuscular or oral antibiotics;
Arteriovenous fistula not requiring treatment;
Pseudoaneurysm requiring thrombin injection or fibrin adhesive injection;
Pseudoaneurysm not requiring treatment;
New onset access site-related neuropathy in the ipsilateral lower extremity not requiring surgical repair;
Ipsilateral pedal pulse diminished by two grades or transiently lost.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Surgical Wound</condition>
  <arm_group>
    <arm_group_label>Manual compression</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using manual compression to reach hemostasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VASCADE™ Vascular Closure System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Cardiva VASCADETM Vascular Closure System (VCS) is indicated for the percutaneous closure of common femoral artery access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular catheterization procedures utilizing 6 Fr or 7 Fr procedural sheaths.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Manual compression</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Manual compression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiva VASCADE™ Vascular Closure System</intervention_name>
    <description>Investigational Hemostatic Vascular Closure System</description>
    <arm_group_label>VASCADE™ Vascular Closure System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Pre-Operative Inclusion Criteria:

          -  Patients undergoing an elective, non-emergent diagnostic or interventional
             endovascular procedure via the common femoral artery using a 6 or 7 Fr introducer
             sheath

        Pre-Operative Exclusion Criteria:

          1. Advanced refusal of blood transfusion, if necessary;

          2. Active systemic or a cutaneous infection or inflammation;

          3. Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids;

          4. Known, significant history of bleeding diathesis, coagulopathy, von Willebrand's
             disease or current platelet count &lt; 100,000 cells/mm3, baseline INR ≥1.8, or
             fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24
             hours);

          5. Severe co-existing morbidities having a life expectancy of less than 30 days;

          6. Currently involved in any other investigational clinical trial;

          7. Ipsilateral femoral arteriotomy within the previous 30 days;

          8. Planned endovascular procedure within the next 30 days;

          9. Previous ipsilateral femoral artery closure using a permanent implant-based closure
             device;

         10. Previous vascular grafts or surgery at the target vessel access site;

         11. History of symptomatic peripheral arterial disease, revascularization or deep vein
             thrombosis in the ipsilateral limb;

         12. Unilateral or bilateral lower extremity amputation(s);

         13. Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than
             30%;

         14. Renal insufficiency (serum creatinine of &gt; 2.5 mg/dl);

         15. Females who are pregnant, planning to become pregnant within 3 months of the
             procedure, or lactating;

         16. Extreme morbid obesity (BMI greater than 45 kg/m2) or underweight (BMI less than 20
             kg/m2);

         17. Unable to routinely walk at least 20 feet without assistance (see protocol);

         18. Known allergy/adverse reaction to bovine derivatives, sodium hyaluronate or hyaluronan
             preparations;

         19. Procedures that extend hospitalization (e.g., staged endovascular procedure, CABG);

         20. Administration of low molecular weight heparin (LMWH) within 8 hours of the procedure.

        Intra-op Exclusion Criteria

          1. An introducer sheath with an overall length greater than 11 cm, or not 6 Fr or 7 Fr
             diameter;

          2. Femoral artery diameter less than 6 mm at access site;

          3. Difficult insertion of procedural sheath or needle stick problems at the onset of the
             procedure (e.g., multiple stick attempts, &quot;back wall stick&quot;, etc.);

          4. Angiographic evidence of more than minimal calcium, atherosclerotic disease, or stent
             within 1 cm of the puncture site;

          5. Overlapping Common Femoral Vein and Femoral Artery at access site;

          6. Placement of ipsilateral venous sheath during procedure;

          7. Arterial access site located not at common femoral artery (e.g., on or below the
             bifurcation, above the lower border of the inferior epigastric artery, or above the
             pelvic brim);

          8. More than one access site required;

          9. Loss of distal pulses in the ipsilateral extremity during the procedure;

         10. Subjects receiving unfractionated heparin with an ACT greater than 300 seconds in the
             absence of a glycoprotein IIb/IIIa inhibitor or greater than 250 seconds in the
             presence of a glycoprotein IIb/IIIa inhibitor (may wait to remove introducer sheath
             until ACT level reaches the target value);

         11. Intra-procedural bleeding around sheath, or suspected intraluminal thrombus, hematoma,
             pseudoaneurysm, or AV fistula;

         12. Systemic hypertension (BP greater than 180/110 mmHg) or hypotension (BP less than
             90/60 mmHg) prior to randomization;

         13. Length of the tissue tract, the distance between the anterior arterial wall and skin,
             is estimated to be less than 2.5 cm;

         14. If the physician deems that a different method should be used to achieve hemostasis of
             the arterial site or that the subject should not attempt ambulation according to the
             protocol requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James B. Hermiller, Jr., MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>The St. Vincent Heart Center of Indiana, St. Vincent Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Hospital</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holmes Regional Medical Center</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Prairie Heart</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's Daughters Medical Center</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terrebonne General Medical Center</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lafayette General Medical Center</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Health System</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Hospital of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAMC Health Education and Research Institute, Inc.</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lehmann KG, Heath-Lange SJ, Ferris ST. Randomized comparison of hemostasis techniques after invasive cardiovascular procedures. Am Heart J. 1999 Dec;138(6 Pt 1):1118-25.</citation>
    <PMID>10577443</PMID>
  </reference>
  <reference>
    <citation>Simon A, Bumgarner B, Clark K, Israel S. Manual versus mechanical compression for femoral artery hemostasis after cardiac catheterization. Am J Crit Care. 1998 Jul;7(4):308-13.</citation>
    <PMID>9656045</PMID>
  </reference>
  <reference>
    <citation>Kussmaul WG 3rd, Buchbinder M, Whitlow PL, Aker UT, Heuser RR, King SB, Kent KM, Leon MB, Kolansky DM, Sandza JG Jr. Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: results of a randomized trial of a novel hemostatic device. J Am Coll Cardiol. 1995 Jun;25(7):1685-92.</citation>
    <PMID>7759724</PMID>
  </reference>
  <reference>
    <citation>Castañeda F, Swischuk JL, Smouse HB, Brady T. Gelatin sponge closure device versus manual compression after peripheral arterial catheterization procedures. J Vasc Interv Radiol. 2003 Dec;14(12):1517-23.</citation>
    <PMID>14654485</PMID>
  </reference>
  <reference>
    <citation>Hoffer EK, Bloch RD. Percutaneous arterial closure devices. J Vasc Interv Radiol. 2003 Jul;14(7):865-85. Review.</citation>
    <PMID>12847195</PMID>
  </reference>
  <reference>
    <citation>Gerckens U, Cattelaens N, Lampe EG, Grube E. Management of arterial puncture site after catheterization procedures: evaluating a suture-mediated closure device. Am J Cardiol. 1999 Jun 15;83(12):1658-63.</citation>
    <PMID>10392872</PMID>
  </reference>
  <reference>
    <citation>Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF, Weissman NJ, Lindsay J, Fuchs S. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003 Oct 15;92(8):930-5.</citation>
    <PMID>14556868</PMID>
  </reference>
  <reference>
    <citation>Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998 Apr 30;17(8):873-90. Erratum in: Stat Med 1999 May 30;18(10):1293.</citation>
    <PMID>9595617</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2011</study_first_posted>
  <results_first_submitted>September 30, 2014</results_first_submitted>
  <results_first_submitted_qc>September 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2014</results_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vascular closure system</keyword>
  <keyword>manual compression</keyword>
  <keyword>femoral arteriotomy</keyword>
  <keyword>percutaneous endovascular procedures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 21, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT01297322/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Manual Compression</title>
          <description>Manual compression: Standard of Care</description>
        </group>
        <group group_id="P2">
          <title>VASCADE™ Vascular Closure System</title>
          <description>Cardiva VASCADE™ Vascular Closure System: Investigational Hemostatic Vascular Closure System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="278"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Manual Compression</title>
          <description>Manual compression: Standard of Care</description>
        </group>
        <group group_id="B2">
          <title>VASCADE™ Vascular Closure System</title>
          <description>Cardiva VASCADE™ Vascular Closure System: Investigational Hemostatic Vascular Closure System</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="142"/>
            <count group_id="B2" value="275"/>
            <count group_id="B3" value="417"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="10.4"/>
                    <measurement group_id="B2" value="61.8" spread="11.2"/>
                    <measurement group_id="B3" value="62" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Hemostasis (TTH)</title>
        <description>Primary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and first observed and confirmed arterial hemostasis.</description>
        <time_frame>Up to 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Manual Compression</title>
            <description>Manual compression: Standard of Care</description>
          </group>
          <group group_id="O2">
            <title>VASCADE™ Vascular Closure System</title>
            <description>Cardiva VASCADE™ Vascular Closure System: Investigational Hemostatic Vascular Closure System</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemostasis (TTH)</title>
          <description>Primary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and first observed and confirmed arterial hemostasis.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="12.4"/>
                    <measurement group_id="O2" value="4.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Combined Access Site-related Major Complications</title>
        <description>Primary safety endpoint
Access site-related bleeding requiring transfusion;
Vascular injury requiring repair (via surgery, ultrasound guided compression, transcatheter embolization or stent graft);
New ipsilateral lower extremity ischemia causing a threat to the viability of the limb and requiring surgical or additional percutaneous intervention. This compromised blood flow is documented by subject symptoms, physical exam and/or a decreased or absent blood flow on lower extremity angiogram.;
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization;
New onset access site-related neuropathy in the ipsilateral lower extremity requiring surgical repair;
Permanent access site-related nerve injury. (&gt; 30 days)</description>
        <time_frame>30 days +/- 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Manual Compression</title>
            <description>Manual compression: Standard of Care</description>
          </group>
          <group group_id="O2">
            <title>VASCADE™ Vascular Closure System</title>
            <description>Cardiva VASCADE™ Vascular Closure System: Investigational Hemostatic Vascular Closure System</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Combined Access Site-related Major Complications</title>
          <description>Primary safety endpoint
Access site-related bleeding requiring transfusion;
Vascular injury requiring repair (via surgery, ultrasound guided compression, transcatheter embolization or stent graft);
New ipsilateral lower extremity ischemia causing a threat to the viability of the limb and requiring surgical or additional percutaneous intervention. This compromised blood flow is documented by subject symptoms, physical exam and/or a decreased or absent blood flow on lower extremity angiogram.;
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization;
New onset access site-related neuropathy in the ipsilateral lower extremity requiring surgical repair;
Permanent access site-related nerve injury. (&gt; 30 days)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Ambulation (TTA)</title>
        <description>Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject stands and walks 20 feet without evidence of arterial re-bleeding</description>
        <time_frame>Up to 1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Manual Compression</title>
            <description>Manual compression: Standard of Care</description>
          </group>
          <group group_id="O2">
            <title>VASCADE™ Vascular Closure System</title>
            <description>Cardiva VASCADE™ Vascular Closure System: Investigational Hemostatic Vascular Closure System</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ambulation (TTA)</title>
          <description>Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject stands and walks 20 feet without evidence of arterial re-bleeding</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="3.1"/>
                    <measurement group_id="O2" value="3.8" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discharge Eligibility (TTDE)</title>
        <description>Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject is medically able to be discharged based solely on the assessment of the access site, as determined by the medical team</description>
        <time_frame>Up to 2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Manual Compression</title>
            <description>Manual compression: Standard of Care</description>
          </group>
          <group group_id="O2">
            <title>VASCADE™ Vascular Closure System</title>
            <description>Cardiva VASCADE™ Vascular Closure System: Investigational Hemostatic Vascular Closure System</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge Eligibility (TTDE)</title>
          <description>Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject is medically able to be discharged based solely on the assessment of the access site, as determined by the medical team</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="3.3"/>
                    <measurement group_id="O2" value="4.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hospital Discharge (TTHD)</title>
        <description>Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject is actually discharged from the hospital</description>
        <time_frame>Up to 2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Manual Compression</title>
            <description>Manual compression: Standard of Care</description>
          </group>
          <group group_id="O2">
            <title>VASCADE™ Vascular Closure System</title>
            <description>Cardiva VASCADE™ Vascular Closure System: Investigational Hemostatic Vascular Closure System</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hospital Discharge (TTHD)</title>
          <description>Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject is actually discharged from the hospital</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="9.8"/>
                    <measurement group_id="O2" value="18.3" spread="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success</title>
        <description>Secondary effectiveness endpoint - ability to deploy the delivery system, deliver the collagen, and achieve hemostasis with VASCADE alone or with adjunctive compression</description>
        <time_frame>Up to 1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VASCADE™ Vascular Closure System</title>
            <description>Cardiva VASCADE™ Vascular Closure System: Investigational Hemostatic Vascular Closure System</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success</title>
          <description>Secondary effectiveness endpoint - ability to deploy the delivery system, deliver the collagen, and achieve hemostasis with VASCADE alone or with adjunctive compression</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Success</title>
        <description>Secondary effectiveness endpoint - attainment of final hemostasis using any method and freedom from major vascular complications through 30 days</description>
        <time_frame>30 days +/- 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Manual Compression</title>
            <description>Manual compression: Standard of Care</description>
          </group>
          <group group_id="O2">
            <title>VASCADE™ Vascular Closure System</title>
            <description>Cardiva VASCADE™ Vascular Closure System: Investigational Hemostatic Vascular Closure System</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Success</title>
          <description>Secondary effectiveness endpoint - attainment of final hemostasis using any method and freedom from major vascular complications through 30 days</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Combined Minor Access Site Complications</title>
        <description>Secondary safety endpoint
Access site-related bleeding requiring greater than 30 minutes to achieve hemostasis;
Access site-related hematoma &gt; 6 cm;
Late access site-related bleeding (following hospital discharge);
Ipsilateral lower extremity arterial emboli;
Ipsilateral deep vein thrombosis;
Access site-related vessel laceration;
Access site wound dehiscence;
Localized access site infection treated with intramuscular or oral antibiotics;
Arteriovenous fistula not requiring treatment;
Pseudoaneurysm requiring thrombin injection or fibrin adhesive injection;
Pseudoaneurysm not requiring treatment;
New onset access site-related neuropathy in the ipsilateral lower extremity not requiring surgical repair;
Ipsilateral pedal pulse diminished by two grades or transiently lost.</description>
        <time_frame>30 days +/- 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Manual Compression</title>
            <description>Manual compression: Standard of Care</description>
          </group>
          <group group_id="O2">
            <title>VASCADE™ Vascular Closure System</title>
            <description>Cardiva VASCADE™ Vascular Closure System: Investigational Hemostatic Vascular Closure System</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Combined Minor Access Site Complications</title>
          <description>Secondary safety endpoint
Access site-related bleeding requiring greater than 30 minutes to achieve hemostasis;
Access site-related hematoma &gt; 6 cm;
Late access site-related bleeding (following hospital discharge);
Ipsilateral lower extremity arterial emboli;
Ipsilateral deep vein thrombosis;
Access site-related vessel laceration;
Access site wound dehiscence;
Localized access site infection treated with intramuscular or oral antibiotics;
Arteriovenous fistula not requiring treatment;
Pseudoaneurysm requiring thrombin injection or fibrin adhesive injection;
Pseudoaneurysm not requiring treatment;
New onset access site-related neuropathy in the ipsilateral lower extremity not requiring surgical repair;
Ipsilateral pedal pulse diminished by two grades or transiently lost.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Manual Compression</title>
          <description>Manual compression: Standard of Care</description>
        </group>
        <group group_id="E2">
          <title>VASCADE™ Vascular Closure System</title>
          <description>Cardiva VASCADE™ Vascular Closure System: Investigational Hemostatic Vascular Closure System</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="142"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Anemia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Access site re-bleeding after initial hemostasis confirmed for 5 minutes</sub_title>
                <description>Access site re-bleeding after initial hemostasis confirmed for 5 minutes</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Ecchymosis - access site</sub_title>
                <description>Ecchymosis - access site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Ecchymosis - nonaccess site</sub_title>
                <description>Ecchymosis - nonaccess site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Hematoma - access site</sub_title>
                <description>Hematoma - access site</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Hypervolemia</sub_title>
                <description>Hypervolemia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Hypotension Requiring Treatment</sub_title>
                <description>Severe Hypotension Requiring Treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <description>Angina</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Atrial fibrillation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Cardiac disorders/symptoms</sub_title>
                <description>Cardiac disorders/symptoms</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Hypertension</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Hypotension</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <description>Ventricular arrhythmia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ENT disorders/symptoms</sub_title>
                <description>ENT disorders/symptoms</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI disorders/symptoms</sub_title>
                <description>GI disorders/symptoms</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort - nonaccess site</sub_title>
                <description>Discomfort - nonaccess site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <description>Fall</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>General disorders/symptoms</sub_title>
                <description>General disorders/symptoms</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Pain - access site</sub_title>
                <description>Pain - access site</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Pain - nonaccess site</sub_title>
                <description>Pain - nonaccess site</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Swelling - nonaccess site</sub_title>
                <description>Swelling - nonaccess site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - access site</sub_title>
                <description>Infection - access site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Retroperitoneal bleeding (hematoma/hemorrhage)</sub_title>
                <description>Retroperitoneal bleeding (hematoma/hemorrhage)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ortho disorders/symptoms</sub_title>
                <description>Ortho disorders/symptoms</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuro - other</sub_title>
                <description>Neuro - other</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Neurological deficit - TIA</sub_title>
                <description>Neurological deficit - TIA</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <description>Vasovagal episode</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <description>Altered mental status</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <description>Renal Insufficiency</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>GU disorders/symptoms</sub_title>
                <description>GU disorders/symptoms</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>Hematuria</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Renal failure/insufficiency</sub_title>
                <description>Renal failure/insufficiency</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>General disorder/respiratory</sub_title>
                <description>General disorder/respiratory</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Respiratory disorders/symptoms</sub_title>
                <description>Respiratory disorders/symptoms</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic disorders / symptoms</sub_title>
                <description>Dermatologic disorders / symptoms</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Erythema - access site</sub_title>
                <description>Erythema - access site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Rash</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Access site-related tissue tract oozing - prolonged</sub_title>
                <description>Access site-related tissue tract oozing - prolonged</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Discomfort - access site</sub_title>
                <description>Discomfort - access site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Thrombosis - peripheral/ non-access site-related</sub_title>
                <description>Arterial Thrombosis - peripheral/ non-access site-related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Embolization - peripheral non-access site-related</sub_title>
                <description>Embolization - peripheral non-access site-related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
              <event>
                <sub_title>Vascular repair - non-device related</sub_title>
                <description>Vascular repair - non-device related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael A. Daniel, Consulting VP Regulatory Affairs</name_or_title>
      <organization>Daniel &amp; Daniel Consulting, LLC</organization>
      <phone>7753922970</phone>
      <email>madaniel@clinregconsult.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

